%0 Journal Article
%T Mucosal Injury during Anti-Cancer Treatment: From Pathobiology to Bedside
%A Camilla Lisanti
%A Carla Corvaja
%A Davide Lombardi
%A Debora Basile
%A Fabio Puglisi
%A Giacomo Pelizzari
%A Lorenzo Gerratana
%A Lucia Bortot
%A Lucia Da Ros
%A Matteo Borghi
%A Michele Bartoletti
%A Paola Di Nardo
%A Silvio Ken Garattini
%J Archive of "Cancers".
%D 2019
%R 10.3390/cancers11060857
%X Mucositis is one of the most common debilitating side effects related to chemotherapy (CT), radiation therapy (RT), targeted agents and immunotherapy. It is a complex process potentially involving any portion of the gastrointestinal tract and injuring the mucosa, leading to inflammatory or ulcerative lesions. Mechanisms and clinical presentation can differ according both to the anatomic site involved (oral or gastrointestinal) and the treatment received. Understanding the pathophysiology and management of mucosal injury as a secondary effect of anti-cancer treatment is an important area of clinical research. Prophylaxis, early diagnosis, and adequate management of complications are essential to increase therapeutic success and, thus, improve the survival outcomes of cancer patients. This review focuses on the pathobiology and management guidelines for mucositis, a secondary effect of old and new anti-cancer treatments, highlighting recent advances in prevention and discussing future research options
%K mucosal injury
%K mucositis
%K mucosal impairment
%K anti-cancer treatments
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6627284/